Skip to main content

The Monthly Seminar on Physical Genomics: Enhancer-Mediated Gene Misregulation In Immune Dysfunction

Friday, November 20, 2026 | 12:00 PM - 1:00 PM CT
Online

November 20th @ 12pm (Central U.S. Time)

Register for the Live Zoom: https://tinyurl.com/pr5nbkf3

Abstract:

Enhancers control cell-type-specific gene expression, and their misregulation alters gene programs and cellular function. Candidate enhancers are commonly identified from chromatin accessibility and histone modifications, but these features do not reveal whether an enhancer is active or which gene it regulates. Active enhancers are themselves transcribed, producing short, unstable, non-polyadenylated enhancer RNAs (eRNAs) that serve as a direct proxy for enhancer activity. Nascent RNA sequencing maps engaged RNA polymerase and therefore measures gene and enhancer activity simultaneously. We developed single-cell nascent RNA sequencing (scGRO-seq), which uses click chemistry to detect eRNAs alongside nascent gene transcripts in the same cell. Because enhancers and their target genes are transcribed in a coordinated manner within individual cells, scGRO-seq builds enhancer–gene maps from basal transcription alone, without external perturbation. We applied this approach to immune dysfunction in pancreatic ductal adenocarcinoma. Mutant p53 cooperates with NF-κB at distal enhancers of the chemokine gene Cxcl1 to increase its transcription. The resulting chemokine overexpression recruits suppressive myeloid cells and excludes T cells. Deleting these enhancers reduced tumor burden, increased T cell infiltration, and restored response to checkpoint blockade. The same enhancers are also active in myeloid and stromal cells within the tumor, indicating that the tumor microenvironment propagates the immunosuppressive program. The cell-type specificity of enhancers and their central role in controlling immune gene expression make them attractive targets for immune reprogramming.

About Dig Bijay Mahat,

Jay Mahat is an Assistant Professor in the Department of Systems Biology at Columbia University and a Principal Investigator in the Laboratory of Immunogenomics at the Chan Zuckerberg Biohub, NY. He earned his B.S. in Biochemistry, Molecular Biology, and Bioinformatics from Towson University, completed his Ph.D. in Molecular Biology and Genetics at Cornell University with John Lis, and conducted postdoctoral research in Dr. Phillip Sharp’s laboratory at the Koch Institute for Integrative Cancer Research at MIT. His lab investigates how non-coding DNA controls gene expression in health and disease. Focusing on enhancers that shape the tumor immune microenvironment in gastrointestinal cancers and those harboring genetic risk variants for autoimmune disorders, his group develops and applies single-cell transcriptomic assays, integrating them with AI and machine-learning frameworks to map gene-regulatory programs at high temporal resolution. Their goal is to identify and target disease-driving enhancers to advance new therapeutic strategies for immune dysfunction diseases.

Sponsored by the Center for Physical Genomics and Engineering, the Cancer and Physical Sciences Program at the Robert H. Lurie Comprehensive Cancer Center, NIH Grants T32GM142604 and U54CA268084, and NSF STC Grant: Genome Intelligence Engineering STC-2535350.

Cost: Cost: Free, registration required at:
https://tinyurl.com/pr5nbkf3

Cost: None

Audience

  • Faculty/Staff
  • Student
  • Public
  • Post Docs/Docs
  • Graduate Students

Contact

Shreevidya Vardhan
(847) 467-1870
Email

Interest

  • Academic (general)

Add Event To My Group

Please sign-in